Healey Community Q&A Webinar: February 12, 2026 | Expanded Access

Why It Matters

Achieving enrollment targets accelerates access to investigational ALS therapy, potentially improving outcomes for patients lacking options. The update also signals Rapa Therapeutics' commitment to transparent, community‑focused drug development.

Key Takeaways

• RAPA-501 EAP met enrollment targets
• Protocol offers expanded access for ALS patients
• Webinar addressed community questions on trial progress
• Future webinars announced via Mass General website
• ALS Link keeps stakeholders updated on research

Pulse Analysis

Amyotrophic lateral sclerosis (ALS) remains one of the most challenging neurodegenerative diseases, with limited therapeutic options and a pressing need for accelerated pathways to experimental treatments. Expanded Access Protocols (EAPs) like RAPA-501 serve as a bridge between early‑stage clinical trials and broader patient availability, allowing individuals who do not qualify for standard trials to receive potentially life‑extending drugs. By meeting its enrollment goals, the RAPA-501 EAP demonstrates both patient demand and the feasibility of scaling such programs within a regulated framework, offering a template for future ALS initiatives.

During the February 12 webinar, Dr. James Berry and Rapa Therapeutics clarified the protocol’s design, eligibility criteria, and safety monitoring procedures, directly responding to community concerns. The successful recruitment underscores robust collaboration between academic institutions, biotech firms, and patient advocacy groups, highlighting how transparent communication can streamline enrollment and maintain public trust. Moreover, the data emerging from the EAP will likely inform subsequent Phase III trials, potentially shortening the timeline for regulatory approval and expanding the therapeutic arsenal for ALS.

Looking ahead, the Healey Center’s commitment to regular webinars and the ALS Link newsletter ensures continuous engagement with patients, caregivers, and clinicians. These channels provide real‑time updates on trial progress, emerging research, and upcoming access opportunities, reinforcing a patient‑centric model that is increasingly valued across the biotech sector. As more companies adopt similar expanded access strategies, the industry may see a shift toward earlier, more inclusive treatment pathways, ultimately reshaping the ALS care landscape.

Original Description

James Berry, MD, MPH of Massachusetts General Hospital was joined by representatives from Rapa Therapeutics to provide an update about the RAPA-501 Expanded Access Protocol (EAP), which recently completed its enrollment goals, and answer questions from the community.

Visit the Mass General website to register for future EAP webinars: https://www.massgeneral.org/neurology/als/research/expanded-access-news

Sign up for the ALS Link to stay up to date about news and research from the Sean M. Healey & AMG Center for ALS: https://lp.constantcontactpages.com/sl/wQfOqgA/ALSLink

Follow MGH Neurology on Facebook (https://www.facebook.com/MGHNeurology/) and X (https://x.com/MGHNeurology)